Literature DB >> 1351263

Neurodevelopment in late infancy after prenatal exposure to benzodiazepines--a prospective study.

L Laegreid1, G Hagberg, A Lundberg.   

Abstract

Growth and neurodevelopment at 6, 10 and 18 months of age have been studied prospectively and longitudinally in a series of 17 children born to mothers who used benzodiazepines (BZD) in therapeutic doses as their only psychotropic drug throughout pregnancy. The results were compared with a group of 29 children born to mothers without any known use of psychotropic drugs. The BZD-exposed children caught up their low mean birth-weight, at an early stage, whereas the slightly decreased head circumference at birth remained at the same low level. In five infants, a pattern of craniofacial anomalies was found. Deviating neurodevelopmental and clinical symptoms and signs were common. The gross motor development was retarded at 6 and 10 months, but was nearly normal at 18 months. Impaired fine motor functions were found on all follow-up occasions. At 18 months, the most prominent finding was a delayed development of pincer grasp. The BZD-exposed children showed deviations in muscle tone and pattern of movements more frequently than children in the reference group. The study suggests that the use of BZD in therapeutic doses throughout pregnancy can have negative effects on the development of children up to 18 months of age. The long-term hazards cannot be evaluated from these results. A further follow-up at early school age is needed and is in progress.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1351263     DOI: 10.1055/s-2008-1071314

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  9 in total

Review 1.  Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review.

Authors:  Hanan El Marroun; Tonya White; Frank C Verhulst; Henning Tiemeier
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-05-27       Impact factor: 4.785

Review 2.  Antiepileptic drugs and neurodevelopment.

Authors:  Gholam K Motamedi; Kimford J Meador
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

3.  Prenatal exposure to anxiolytics and hypnotics and language competence at 3 years of age.

Authors:  Ingvild Odsbu; Svetlana Skurtveit; Randi Selmer; Christine Roth; Sonia Hernandez-Diaz; Marte Handal
Journal:  Eur J Clin Pharmacol       Date:  2014-12-30       Impact factor: 2.953

Review 4.  [Neurotoxicity of general anesthetics in childhood: does anesthesia leave its mark on premature babies, newborns and infants?].

Authors:  B Sinner; K Becke; K Engelhard
Journal:  Anaesthesist       Date:  2013-02       Impact factor: 1.041

5.  Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.

Authors:  L R Dolovich; A Addis; J M Vaillancourt; J D Power; G Koren; T R Einarson
Journal:  BMJ       Date:  1998-09-26

Review 6.  Pharmacologic interventions for pregnant women enrolled in alcohol treatment.

Authors:  Erica J Smith; Steve Lui; Mishka Terplan
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

7.  Neurodegeneration in newborn rats following propofol and sevoflurane anesthesia.

Authors:  Sven Bercker; Bettina Bert; Petra Bittigau; Ursula Felderhoff-Müser; Christoph Bührer; Chrysanthy Ikonomidou; Mirjam Weise; Udo X Kaisers; Thoralf Kerner
Journal:  Neurotox Res       Date:  2009-05-27       Impact factor: 3.911

8.  Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study.

Authors:  Ragnhild E Brandlistuen; Eivind Ystrom; Sonia Hernandez-Diaz; Svetlana Skurtveit; Randi Selmer; Marte Handal; Hedvig Nordeng
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

9.  Educational achievement at age 9.5 years of children born to mothers maintained on methadone during pregnancy.

Authors:  Samantha J Lee; Lianne J Woodward; Jacqueline M T Henderson
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.